About
Another intriguing observation is that prostate-specific antigen (PSA), a marker for prostate cancer, is significantly lower in type 2 diabetics and this is related to their lower plasma testosterone concentrations (46). This is in contrast to what was found in the MMAS study where total testosterone levels were unrelated to all-cause mortality (34,35). In fact, epidemiological analyses have found that HDL levels are positively linked to testosterone levels in middle-aged men. The Massachusetts Male Ageing Study (MMAS) measured a combination of testosterone levels and hypogonadal symptoms and found between 6% and 12% of men had symptomatic androgen deficiency (21).Several other medical conditions can mimic the symptoms of low testosterone, including depression, sleep apnea, hypothyroidism and anemia, among others. "These may include reduced muscle mass, decreased bone density with a higher risk of fractures, increased chances of developing diabetes, and cardiovascular disease, infertility and depression," Baumgarten said. Low testosterone can affect mental health and energy levels, often causing fatigue, irritability, mood swings and even depression. Prostate cells are stimulated by testosterone, so be extra vigilant about cancer screenings. If you are treated with testosterone, your doctor will need to see you regularly, along with blood tests. Method of treatment depends on the cause of low testosterone, the patient’s preferences, cost, tolerance, and concern about fertility. Hypogonadism can be treated with the use of doctor-prescribed testosterone replacement therapy.
Signs and symptoms of central hypogonadism may involve headaches, impaired vision, double vision, milky discharge from the breast, and symptoms caused by other hormone problems. Physicians measure gonadotropins (LH and FSH) to distinguish primary from secondary hypogonadism. Deficiency of sex hormones can result in defective primary or secondary sexual development, or withdrawal effects (e.g., premature menopause) in adults.
Elevated haematocrit values above 54% require action – usually therapy should be stopped until the values decrease to a safe level. Any significant increase in PSA deserves a referral to a urologist and treatment should be discontinued until evaluated. AEs, adverse events; BMD, bone mineral density; DRE, digital rectal examination; PSA, prostate-specific antigen.
In some patients with primary hypogonadism, testosterone levels may be within the normal range, but the increased LH and FSH indicate that the pituitary gland is trying to compensate for a deficiency and treatment may still be needed. Any male who thinks he may have low testosterone levels should seek medical advice, as treatment can reverse most of the symptoms and risks of male hypogonadism. Before starting treatment with testosterone, a blood test to measure a hormone produced by the prostate called PSA (prostate-specific antigen) is carried out (PSA levels are elevated in prostate cancer). However, testosterone therapy does not have sufficient evidence of prostate cancer risk to recommend mandatory screening.
Primary hypogonadism happens when your testicles aren’t making normal levels of testosterone. Providers call it male hypogonadism when you have symptoms along with these low levels. It is important to mention that the occurrence of prostate cancer in patients with type 2 diabetes is lower than that seen in the general population.
It can be due to a testicular disorder or the result of a disease process involving the hypothalamus and pituitary gland. A web-based project by the Society for Endocrinology that aims to give patients and the general public access to reliable online information on endocrine science. Current research suggests that this effect occurs in only a small group of ageing men.
As a result of the concerns about prostate cancer it is important to monitor PSA levels and perform a DRE regularly during the course of treatment. Studies with hypogonadal men have demonstrated that once testosterone levels are restored to a stable normal range, there is an improvement in libido, sexual function, mood and energy levels relatively early in the course of treatment (78,84–86). When looking at the treatment options, it is important to keep in mind that the goal of testosterone replacement therapy is to increase blood testosterone concentrations to the normal (eugonadal) range and to match the most appropriate treatment to the individual patient. Elevated LH and FSH levels suggest primary hypogonadism, whereas low or low-normal LH and FSH levels suggest secondary hypogonadism. The Endocrine Society recommends that the diagnosis of testosterone be made in men who have both consistent signs and symptoms and low total testosterone levels. A negative view of testosterone’s impact on cardiovascular disease comes from the observation that high-density lipoprotein (HDL) cholesterol levels decrease in patients on oral testosterone therapy, or when taken in supraphysiological doses by athletes (29,30). It should be noted that low testosterone can be caused by a combination of both primary and secondary hypogonadism (also called mixed hypogonadism) that reflects defects in the hypothalamus and/or the pituitary as well as the testes.
While historically, men with prostate cancer risk were warned against testosterone therapy, that has shown to be a myth. So, at the present time, there is a lack of conclusive evidence that testosterone therapy in hypogonadal men increases the risk of prostate cancer, and there is no evidence that it will promote subclinical cancer to metastatic cancer. One of the striking things about a study published in 2007 was that physicians’ number one fear about initiating testosterone therapy was their perception that it increases the risk of prostate cancer.